ACET

ACET

Adicet Bio Inc

Adicet Bio develops allogeneic gamma delta T cell therapies targeting autoimmune diseases and cancer. Its lead candidate, prulacabtagene leucel, targets CD20, while ADI-212 aims at prostate-specific membrane antigen, enhancing cancer treatment options.

⚕️ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago $72today

Score Overview

1 Year
Score
Net Growth15.26%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score3.3
Net Growth-59.64%
Net Trend60%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-8x
Net Trend38%
Net Income Consistency
Rev Growth-100.00%
Rev Trend25%
Revenue Consistency

See the full market ranking →

Adicet Bio Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 17M to $ 0.00 and net income went from -$ 36M to -$ 116M. Revenue increased in 1 of those 5 years; net income in 3.

Adicet Bio Inc currently holds a 5-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 8.26
1 Year2025-08-12
$ 10.22-19.21%
5 Years2021-08-12
$ 114.08-92.76%
All Time2018-01-26
$ 1.89K-99.56%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 98M$ 33M
2025$ 0.00-$ 116M$ 158M
2024$ 0.00-$ 117M$ 176M
2023$ 0.00-$ 142M$ 159M
2022$ 24M-$ 69M$ 257M
2021$ 9M-$ 61M$ 277M
2020$ 17M-$ 36M$ 94M
2019$ 995K-$ 28M$ 62M
IPO2018$ 8M-$ 9M$ 108M

Explore beyond ACET

You're looking at Adicet Bio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies